title: Lysophosphatidic acid induces histamine release from mast cells and skin fragments.
abstract: The present study examined whether lysophosphatidic acid (LPA) induces histamine release and the role of Rho-associated protein kinase (ROCK) in histamine release utilizing Y-27632, an inhibitor of ROCK. Rat peritoneal mast cells and mouse skin fragments were challenged with LPA; subsequently, histamine contents were measured by spectrofluorometric assay. LPA-induced histamine release from mast cells and skin fragments occurred in a time- and dose-dependent manner Pretreatment with Y-27632 inhibited LPA-induced histamine release in a dose-dependent fashion. LPA-induced histamine release was not influenced by calcium-free conditions; however, A23187-induced histamine release decreased significantly. TMB-8, an intracellular calcium antagonist, dose-dependently inhibited the histamine release under these conditions. Additionally, Y-27632 scarcely affected A23187-induced histamine release. These findings suggest that LPA-induced histamine release may be attributable to calcium release from intracellular stores. Moreover, ROCK participates in the extracellular calcium-independent process of LPA-induced histamine release.
authors.affiliation: Department of Pharmacology, School of Pharmaceutical Sciences, Showa University, Tokyo, Japan.
authors.forename: Terumasa
authors.initials: T
authors.lastname: Hashimoto
authors.forename: Hisayuki
authors.initials: H
authors.lastname: Ohata
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Momose
authors.forename: Kazuo
authors.initials: K
authors.lastname: Honda
mesh_terms: D000577:Amides / Q000494:pharmacology; D000818:Animals; D000001:Calcimycin / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors; D005707:Gallic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D006636:Histamine Release / Q000187:drug effects*; D066298:In Vitro Techniques; D047908:Intracellular Signaling Peptides and Proteins; D007476:Ionophores / Q000494:pharmacology; D008246:Lysophospholipids / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D008297:Male; D008407:Mast Cells / Q000187:drug effects* / Q000378:metabolism; D051379:Mice; D008813:Mice, Inbred ICR; D010537:Peritoneum / Q000166:cytology; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012867:Skin / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D013045:Species Specificity; D013997:Time Factors; D054460:rho-Associated Kinases
chemical_list: D000577:Amides; D002121:Calcium Channel Blockers; D004791:Enzyme Inhibitors; D047908:Intracellular Signaling Peptides and Proteins; D007476:Ionophores; D008246:Lysophospholipids; D011725:Pyridines; C108830:Y 27632; D000001:Calcimycin; C006014:8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate; D005707:Gallic Acid; D017346:Protein Serine-Threonine Kinases; D054460:rho-Associated Kinases; C032881:lysophosphatidic acid; D002118:Calcium